Spruce Biosciences(SPRB)
Focus: Spruce Biosciences is a public biotechnology company focused on treatments for HPA axis disorders, particularly congenital adrenal hyperplasia and related endocrine conditions. The company is early-stage with minimal commercial revenue and operates as a clinical-stage biotech with Phase 2 and Phase 3 programs.
Profile data last refreshed 7h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Spruce Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Spruce Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Spruce Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$5M
Pipeline & Clinical Trials
PHASE_2
Clinical Trials (1)
NCT03687242Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Phase 2Help build intelligence for Spruce Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.